Radiofrequency Ablation in TIR3A Nodules With Negative Genetic Evaluation

Launched by ISTITUTO AUXOLOGICO ITALIANO · Mar 9, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a treatment called radiofrequency ablation for patients with specific types of thyroid nodules known as TIR3A nodules. These are nodules that have uncertain results from initial testing but have been determined to have a low risk of cancer after a negative genetic test. The goal of the study is to see if this treatment can safely reduce the size of these nodules and improve any symptoms the patients may be experiencing.

To participate in this trial, patients must have a TIR3A thyroid nodule and a negative genetic test result. They should also be able to understand the study and sign consent to join. Before the treatment, participants will undergo some blood tests to check various hormone and antibody levels. If someone has a different type of thyroid nodule, a positive genetic test, or is unable to provide consent, they won't be eligible for the study. This trial is actively looking for participants, and it welcomes individuals of all ages and genders who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with thyroid nodule eligible for radiofrequency ablation, with low-risk indeterminate lesion cytology (TIR3A) and negative genetic test for mutations associated with thyroid carcinoma
• Exclusion Criteria:
• • Patients who are not able to sign the informed consent
• • Patients with contraindications to radiofrequency ablation
• • Patients with cytology different from TIR3A
• • Patients with positive genetic test for mutations associated with thyroid carcinoma